Laboratory assessment of factor viii inhibitor titer the north american specialized coagulation laboratory association experience

American Journal of Clinical Pathology

Volumn 131, Issue 4, 2009, Pages 552-558

  Peerschke, Ellinor I B ^a   Castellone, Donna D ^a   Ledford Kraemer, Marlies ^b   Van Cott, Elizabeth M ^c   Meijer, Piet ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CLOT ED   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ECAT Foundation   (Netherlands)

Author keywords

Coagulation; ECAT; Factor VIII inhibitor titer; Hemophilia; NASCOLA; North american specialized coagulation laboratory association; Proficiency testing

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD CLOTTING; DIAGNOSTIC ACCURACY; LABORATORY TEST; NORTH AMERICA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; BLOOD EXAMINATION; HEMOPHILIA A; HOSPITAL LABORATORY; HUMAN; IMMUNOLOGY; METHODOLOGY; QUALITY CONTROL; STANDARD;

AUTOANTIBODIES; FACTOR VIII; HEMATOLOGIC TESTS; HEMOPHILIA A; HUMANS; LABORATORIES, HOSPITAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY;

EID: 65349196134     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPMKP94CODILWS     Document Type: Article

References (21)

1. Gouw SC, van den Berg HM, Le Cessie S, et al. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5:1383-1390.
2. Barrow RT, Lollar P. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. J Thromb Haemost. 2006;4:2223-2229.
3. Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol. 1959;5:379-395.
4. Biggs R, Austen DE, Denson DW, et al. The mode of action of antibodies which destroy factor VIII, II: antibodies which give complex concentration graphs. Br J Haematol. 1972;23:137-155.
5. Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol. 1976;16:369-382.
6. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872.
7. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247-251.
8. Regnault V, Stoltz JF. Quantitation of factor VIII antibodies by an enzyme-linked immunoassay method [letter]. Blood. 1994;83:1155-1156.
9. Martin PG, Sukhu K, Chambers E, et al. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol. 1999;21:125-128.
10. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia. 2000;6:150-157.
11. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia: a review. Semin Thromb Hemost. 2003;29:69-75.
12. Hay CRM, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Center Doctors Organisation. Br J Haematol. 2006;133:591-605.
13. Smith OP. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors. Pathophysiol Haemost Thromb. 2002;32(suppl 1):22-25.
14. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8:280-287.
15. Hay C, Recht M, Carcao M, et al. Current and future approaches to inhibitor management and aversion. Semin Thromb Hemost. 2002;32(suppl 2):15-21.
16. Giles AR, Verbruggen B, Rivard GE, et al A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada: Association of Hemophilia Centre Directors of Canada, Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost. 1998;79:872-875.
17. Favalaro EJ, Bonar R Duncan E, et al. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi- center evaluation. Thromb Haemost. 2006;96:73-78.
18. Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med. 1993;328:453-459.
19. Towfighi F, Gharagozlou S, Sharifian RA, et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol. 2005;114:84-90.
20. Lindgren A, Wadenvik H, Tengbron L. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia. 2002;8:644-648.
21. College of American Pathologists Surveys, CGE-A, 2008.